These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 10425578)

  • 1. Immunological disorders in inflammatory bowel disease and immunotherapeutic implications.
    Amati L; Caradonna L; Jirillo E; Caccavo D
    Ital J Gastroenterol Hepatol; 1999 May; 31(4):313-25. PubMed ID: 10425578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance.
    Caradonna L; Amati L; Magrone T; Pellegrino NM; Jirillo E; Caccavo D
    J Endotoxin Res; 2000; 6(3):205-14. PubMed ID: 11052175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of inflammatory bowel diseases: current concepts and future perspectives.
    Neurath MF
    Arch Immunol Ther Exp (Warsz); 2000; 48(2):81-4. PubMed ID: 10807047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune mechanisms in chronic inflammatory bowel disease.
    Braegger CP; MacDonald TT
    Ann Allergy; 1994 Feb; 72(2):135-41. PubMed ID: 8109803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current concept of the role of monocytes/macrophages in inflammatory bowel disease--balance of proinflammatory and immunosuppressive mediators.
    Lügering N; Kucharzik T; Stoll R; Domschke W
    Ital J Gastroenterol Hepatol; 1998 Jun; 30(3):338-44. PubMed ID: 9759608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunology in medical practice. IV. Inflammatory bowel diseases: pathogenic starting points for specific therapy].
    van Deventer SJ
    Ned Tijdschr Geneeskd; 1997 Oct; 141(41):1956-9. PubMed ID: 9550744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New mediators of immunity and inflammation in inflammatory bowel disease.
    Monteleone G; Fina D; Caruso R; Pallone F
    Curr Opin Gastroenterol; 2006 Jul; 22(4):361-4. PubMed ID: 16760750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease.
    Caradonna L; Amati L; Lella P; Jirillo E; Caccavo D
    Am J Gastroenterol; 2000 Jun; 95(6):1495-502. PubMed ID: 10894586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immunomodulation strategy targeted towards immunocompetent cells or cytokines in inflammatory bowel diseases (IBD).
    Heresbach D; Sémana G; Gosselin M; Bretagne MG
    Eur Cytokine Netw; 1999 Mar; 10(1):7-15. PubMed ID: 10210767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency.
    Mannon PJ; Fuss IJ; Dill S; Friend J; Groden C; Hornung R; Yang Z; Yi C; Quezado M; Brown M; Strober W
    Gastroenterology; 2006 Sep; 131(3):748-56. PubMed ID: 16952544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of vasoactive intestinal peptide receptor 1 expression in inflammatory bowel disease.
    Yukawa T; Oshitani N; Yamagami H; Watanabe K; Higuchi K; Arakawa T
    Int J Mol Med; 2007 Aug; 20(2):161-7. PubMed ID: 17611633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A primary dysregulation in the immunoregulatory role of the intestinal mucosal epithelial cell in inflammatory bowel disease pathogenesis? Biology of inflammatory response as tissue pattern entities in Crohn's versus ulcerative colitis.
    Agius LM
    J Theor Biol; 2004 Mar; 227(2):219-28. PubMed ID: 14990386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production.
    Liu Z; Colpaert S; D'Haens GR; Kasran A; de Boer M; Rutgeerts P; Geboes K; Ceuppens JL
    J Immunol; 1999 Oct; 163(7):4049-57. PubMed ID: 10491009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in biological therapy for inflammatory bowel disease.
    Kurtovic J; Segal I
    Trop Gastroenterol; 2004; 25(1):9-14. PubMed ID: 15303463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immune response in inflammatory bowel disease.
    Brown SJ; Mayer L
    Am J Gastroenterol; 2007 Sep; 102(9):2058-69. PubMed ID: 17561966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: the aetiopathogenesis of inflammatory bowel disease--immunology and repair mechanisms.
    Dignass AU; Baumgart DC; Sturm A
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():9-17. PubMed ID: 15352888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pathophysiologic rationale for biological therapies in inflammatory bowel disease.
    Gordon JN; Di Sabatino A; Macdonald TT
    Curr Opin Gastroenterol; 2005 Jul; 21(4):431-7. PubMed ID: 15930983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NF-kappaB in inflammatory bowel disease.
    Atreya I; Atreya R; Neurath MF
    J Intern Med; 2008 Jun; 263(6):591-6. PubMed ID: 18479258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.
    Vuckovic S; Florin TH; Khalil D; Zhang MF; Patel K; Hamilton I; Hart DN
    Am J Gastroenterol; 2001 Oct; 96(10):2946-56. PubMed ID: 11693331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of innate immunity in the development of inflammatory and autoimmune diseases.
    Tlaskalová-Hogenová H; Tucková L; Stepánková R; Hudcovic T; Palová-Jelínková L; Kozáková H; Rossmann P; Sanchez D; Cinová J; Hrncír T; Kverka M; Frolová L; Uhlig H; Powrie F; Bland P
    Ann N Y Acad Sci; 2005 Jun; 1051():787-98. PubMed ID: 16127016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.